Using two newly developed immunoassays tested in three clinical cohorts, this study highlights CSF DOPA decarboxylase as a promising biomarker for differentiating dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls.
- Katharina Bolsewig
- Giovanni Bellomo
- Charlotte E. Teunissen